599 related articles for article (PubMed ID: 24138824)
1. Lgr5 promotes cancer stemness and confers chemoresistance through ABCB1 in colorectal cancer.
Liu YS; Hsu HC; Tseng KC; Chen HC; Chen SJ
Biomed Pharmacother; 2013 Oct; 67(8):791-9. PubMed ID: 24138824
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells.
Ying J; Tsujii M; Kondo J; Hayashi Y; Kato M; Akasaka T; Inoue T; Shiraishi E; Inoue T; Hiyama S; Tsujii Y; Maekawa A; Kawai S; Fujinaga T; Araki M; Shinzaki S; Watabe K; Nishida T; Iijima H; Takehara T
Int J Oncol; 2015 Apr; 46(4):1551-9. PubMed ID: 25625841
[TBL] [Abstract][Full Text] [Related]
3. LGR5 promotes cancer stem cell traits and chemoresistance in cervical cancer.
Cao HZ; Liu XF; Yang WT; Chen Q; Zheng PS
Cell Death Dis; 2017 Sep; 8(9):e3039. PubMed ID: 28880275
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells.
Kemper K; Prasetyanti PR; De Lau W; Rodermond H; Clevers H; Medema JP
Stem Cells; 2012 Nov; 30(11):2378-86. PubMed ID: 22969042
[TBL] [Abstract][Full Text] [Related]
5. SW480 colorectal cancer cells that naturally express Lgr5 are more sensitive to the most common chemotherapeutic agents than Lgr5-negative SW480 cells.
Planutis AK; Holcombe RF; Planoutene MV; Planoutis KS
Anticancer Drugs; 2015 Oct; 26(9):942-7. PubMed ID: 26196680
[TBL] [Abstract][Full Text] [Related]
6. Co-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer.
Wu W; Cao J; Ji Z; Wang J; Jiang T; Ding H
Oncotarget; 2016 Dec; 7(49):81144-81155. PubMed ID: 27835894
[TBL] [Abstract][Full Text] [Related]
7. LGR5 regulates survival through mitochondria-mediated apoptosis and by targeting the Wnt/β-catenin signaling pathway in colorectal cancer cells.
Hsu HC; Liu YS; Tseng KC; Tan BC; Chen SJ; Chen HC
Cell Signal; 2014 Nov; 26(11):2333-42. PubMed ID: 25025569
[TBL] [Abstract][Full Text] [Related]
8. NANOGP8 is the key regulator of stemness, EMT, Wnt pathway, chemoresistance, and other malignant phenotypes in gastric cancer cells.
Ma X; Wang B; Wang X; Luo Y; Fan W
PLoS One; 2018; 13(4):e0192436. PubMed ID: 29689047
[TBL] [Abstract][Full Text] [Related]
9. LGR5 Is a Gastric Cancer Stem Cell Marker Associated with Stemness and the EMT Signature Genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1.
Wang B; Chen Q; Cao Y; Ma X; Yin C; Jia Y; Zang A; Fan W
PLoS One; 2016; 11(12):e0168904. PubMed ID: 28033430
[TBL] [Abstract][Full Text] [Related]
10. Colorectal cancer stem cell and chemoresistant colorectal cancer cell phenotypes and increased sensitivity to Notch pathway inhibitor.
Huang R; Wang G; Song Y; Tang Q; You Q; Liu Z; Chen Y; Zhang Q; Li J; Muhammand S; Wang X
Mol Med Rep; 2015 Aug; 12(2):2417-24. PubMed ID: 25936357
[TBL] [Abstract][Full Text] [Related]
11. Autophagy contributes to the enrichment and survival of colorectal cancer stem cells under oxaliplatin treatment.
Yang HZ; Ma Y; Zhou Y; Xu LM; Chen XJ; Ding WB; Zou HB
Cancer Lett; 2015 May; 361(1):128-36. PubMed ID: 25749420
[TBL] [Abstract][Full Text] [Related]
12. LGR5 is required for the maintenance of spheroid-derived colon cancer stem cells.
Chen X; Wei B; Han X; Zheng Z; Huang J; Liu J; Huang Y; Wei H
Int J Mol Med; 2014 Jul; 34(1):35-42. PubMed ID: 24789370
[TBL] [Abstract][Full Text] [Related]
13. 4-Acetylantroquinonol B inhibits colorectal cancer tumorigenesis and suppresses cancer stem-like phenotype.
Chang TC; Yeh CT; Adebayo BO; Lin YC; Deng L; Rao YK; Huang CC; Lee WH; Wu AT; Hsiao M; Wu CH; Wang LS; Tzeng YM
Toxicol Appl Pharmacol; 2015 Oct; 288(2):258-68. PubMed ID: 26235807
[TBL] [Abstract][Full Text] [Related]
14. Expression of Lgr5, a marker of intestinal stem cells, in colorectal cancer and its clinicopathological significance.
He S; Zhou H; Zhu X; Hu S; Fei M; Wan D; Gu W; Yang X; Shi D; Zhou J; Zhou J; Zhu Z; Wang L; Li D; Zhang Y
Biomed Pharmacother; 2014 Jun; 68(5):507-13. PubMed ID: 24751002
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer.
Hsu HC; Liu YS; Tseng KC; Hsu CL; Liang Y; Yang TS; Chen JS; Tang RP; Chen SJ; Chen HC
Int J Colorectal Dis; 2013 Nov; 28(11):1535-46. PubMed ID: 23784051
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor-beta1 promotes the migration and invasion of sphere-forming stem-like cell subpopulations in esophageal cancer.
Yue D; Zhang Z; Li J; Chen X; Ping Y; Liu S; Shi X; Li L; Wang L; Huang L; Zhang B; Sun Y; Zhang Y
Exp Cell Res; 2015 Aug; 336(1):141-9. PubMed ID: 26096658
[TBL] [Abstract][Full Text] [Related]
17. Colorectal Cancer Stem Cells Acquire Chemoresistance Through the Upregulation of F-Box/WD Repeat-Containing Protein 7 and the Consequent Degradation of c-Myc.
Izumi D; Ishimoto T; Miyake K; Eto T; Arima K; Kiyozumi Y; Uchihara T; Kurashige J; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Watanabe M; Goel A; Tan P; Baba H
Stem Cells; 2017 Sep; 35(9):2027-2036. PubMed ID: 28699179
[TBL] [Abstract][Full Text] [Related]
18. Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer.
Cai Z; Ke J; He X; Yuan R; Chen Y; Wu X; Wang L; Wang J; Lan P; Wu X
Ann Surg Oncol; 2014 Jan; 21(1):179-88. PubMed ID: 23907312
[TBL] [Abstract][Full Text] [Related]
19. Chronic chemotherapeutic stress promotes evolution of stemness and WNT/beta-catenin signaling in colorectal cancer cells: implications for clinical use of WNT-signaling inhibitors.
Ayadi M; Bouygues A; Ouaret D; Ferrand N; Chouaib S; Thiery JP; Muchardt C; Sabbah M; Larsen AK
Oncotarget; 2015 Jul; 6(21):18518-33. PubMed ID: 26041882
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of stemlike cells in human esophageal adenocarcinoma and normal epithelial cell lines.
Zhao R; Quaroni L; Casson AG
J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1192-9. PubMed ID: 22980068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
